Pfizer (FRA:PFE) Ending Cash Position : €2,675 Mil (As of Dec. 2023)

View and export this data going back to 1951. Start your Free Trial

What is Pfizer Ending Cash Position?

Pfizer's Ending Cash Position for the quarter that ended in Dec. 2023 was €2,675 Mil.

Pfizer's quarterly Ending Cash Position increased from Jun. 2023 (€2,490 Mil) to Sep. 2023 (€3,029 Mil) but then declined from Sep. 2023 (€3,029 Mil) to Dec. 2023 (€2,675 Mil).

Pfizer's annual Ending Cash Position declined from Dec. 2021 (€1,755 Mil) to Dec. 2022 (€442 Mil) but then increased from Dec. 2022 (€442 Mil) to Dec. 2023 (€2,675 Mil).

Pfizer Ending Cash Position Historical Data

The historical data trend for Pfizer's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Ending Cash Position Chart

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

1,215.00

1,500.15

1,754.96

441.79

2,674.89

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															441.79	2,075.35	2,490.25	3,029.32	2,674.89

Pfizer Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pfizer's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	430.073	+	2244.816
	=	2,675

Pfizer's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2963.744	+	-288.855
	=	2,675

Pfizer Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pfizer's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (FRA:PFE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (FRA:PFE) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.